ClinicalTrials.gg

Program

TQ-B3234 capsules

Also written as “TQ-B3234 capsule” and “TQ-B3234”.

Its studies are mostly in Neurofibroma, Plexiform · Neurofibromatoses, led by Sino Biopharmaceutical.

Furthest: phase 3, since Feb 3, 20263 company-led studies, 1 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical31 open or runningphase 3since Feb 3, 2026Dec 15, 2016Dec 2027phase 3 · NCT07407803

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 15, 2016First study: phase 1 study in Advanced CancerFirst studyNCT02996838 · 20 enrolled · China
  2. Sep 3, 2021Phase 1 study in NeurofibromatosesNCT05107037 · 120 enrolled · China
  3. Feb 3, 2026Phase 3 study in Neurofibroma, PlexiformPhase 3 reachedNCT07407803 · 177 planned · China

Ahead

  1. Dec 2027Primary completion: phase 3 study in Neurofibroma, PlexiformNCT07407803

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07407803Neurofibroma, Plexiform · China3RecruitingDec 2027177
NCT05107037Neurofibromatoses · China1UNKNOWNDec 2023120
NCT02996838Advanced Cancer · China1UNKNOWNDec 202020

How it is read

Names in the registry

  • “TQ-B3234 capsules”, 1 entry
  • “TQ-B3234 capsule”, 1 entry
  • “TQ-B3234”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.